Granules India gets licences from MPP to market Nirmatrelvir, Ritonavir

19 Mar 2022 Evaluate

Granules India (GIL) has received a license from Medicines Patent Pool (MPP) to manufacture and market generic versions of Pfizer’s oral treatment nirmatrelvir which will be co-packaged with ritonavir for treatment of COVID-19. The licenses are applicable for both active pharmaceutical ingredients (API) and finished products, in tablet form, of nirmatrelvir, Ritonavir. 

Nirmatrelvir is an inhibitor of SARS-CoV-2 3CL-like protease that prevents polyprotein cleavage of proteins necessary for SARS-CoV-2 genome replication. Nirmatrelvir in combination with ritonavir (under the Pfizer brand name PAXLOVID) is currently approved for emergency use, in the US, Canada and many other countries for the treatment of mild-to-moderate COVID-19 in certain adults and pediatric patients.

The product will be made at Granules manufacturing facilities in India that are approved by global regulatory agencies including USFDA. The license received by GIL will enable the company to launch the product in India and 94 other countries worldwide.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).

Granules India Share Price

570.15 0.55 (0.10%)
01-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.